Metropolis Healthcare Reports Q1 FY26-27 Business Update with 16% Revenue Growth

Metropolis Healthcare Limited announced an approximate 16% year-on-year revenue growth for the quarter ended June 30, 2026 (Q1 FY26-27). This growth was primarily fueled by an increase in patient volumes, complemented by realization benefits from changes in its product mix. The company also reported an improvement in EBITDA margins on a year-on-year basis, consistent with its guidance.

Key highlights

• Consolidated revenue grew by approximately 16% year-on-year for Q1 FY26-27.
• Patient volumes were the primary driver of revenue growth, along with benefits from product mix changes.
• The TruHealth Wellness and Specialty segments were identified as the fastest-growing segments for the quarter.
• B2C volumes saw healthy growth, attributed to an expanded network of diagnostic centers.
• B2B volumes also increased, supported by higher wallet share and new customer acquisition, alongside improved service quality.
• EBITDA margins improved year-on-year, aligning with stated guidance, and remained largely stable quarter-on-quarter.

What drove it

The approximate 16% revenue growth was largely driven by an increase in patient volumes, further supported by realization benefits derived from a shift in the company's product mix. The healthy volume growth in the Business-to-Consumer (B2C) segment stemmed from increased throughput across an expanded center network. Within the Business-to-Business (B2B) segment, growth was bolstered by an increased wallet share from existing partners and the acquisition of new customers, which the company attributed to improved service quality and delivery levels.

Context

Metropolis Healthcare's Q1 FY26-27 revenue growth of approximately 16% year-on-year follows a period of higher growth rates in previous quarters. For Q4 FY25-26, the company reported a revenue growth of nearly 23% year-on-year, alongside a significant 71% year-on-year increase in EBITDA and a 75% year-on-year rise in PAT. In Q3 FY25-26, revenue grew by 26% year-on-year, and in Q2 FY25-26, it grew by 23% year-on-year. The consistent year-on-year improvement in EBITDA margins in Q1 FY26-27 aligns with the positive margin trends observed in the preceding fiscal year.

Why it matters

The business update highlights Metropolis Healthcare's continued focus on expanding its operational reach and enhancing customer engagement, evident in the growth across both B2C and B2B channels. The strong performance of the TruHealth Wellness and Specialty segments indicates successful diversification and strategic positioning in high-growth areas. Sustained patient volume growth, coupled with improved EBITDA margins, reflects operational efficiency and effective management of its service offerings. These factors are important indicators of the company's underlying business health and execution capabilities.

What to watch

A detailed update will follow once Metropolis Healthcare's Board of Directors approves the financial results for Q1 FY26-27. The audited financial results are expected to provide further insights into the company's performance and segmental contributions. (Source: NSE 106686958)